Section of Experimental Virology, Institute of Medical Microbiology, Center for Molecular Biomedicine (CMB), Jena University Hospital, Hans-Knoell-Str. 2, D-07745 Jena, Germany.
Institute of Molecular Cell Biology, Center for Molecular Biomedicine (CMB), Jena University Hospital, Hans-Knoell-Str. 2, D-07745 Jena, Germany.
Int J Mol Sci. 2022 Jun 21;23(13):6880. doi: 10.3390/ijms23136880.
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing the coronavirus disease-19 (COVID-19) is still challenging healthcare systems and societies worldwide. While vaccines are available, therapeutic strategies are developing and need to be adapted to each patient. Many clinical approaches focus on the repurposing of approved therapeutics against other diseases. However, the efficacy of these compounds on viral infection or even harmful secondary effects in the context of SARS-CoV-2 infection are sparsely investigated. Similarly, adverse effects of commonly used therapeutics against lifestyle diseases have not been studied in detail. Using mono cell culture systems and a more complex chip model, we investigated the effects of the acetylsalicylic acid (ASA) salt D,L-lysine-acetylsalicylate + glycine (LASAG) on SARS-CoV-2 infection in vitro. ASA is commonly known as Aspirin and is one of the most frequently used medications worldwide. Our data indicate an inhibitory effect of LASAG on SARS-CoV-2 replication and SARS-CoV-2-induced expression of pro-inflammatory cytokines and coagulation factors. Remarkably, our data point to an additive effect of the combination of LASAG and the antiviral acting drug remdesivir on SARS-CoV-2 replication in vitro.
严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）引起的冠状病毒病 19（COVID-19）仍然对全球的医疗保健系统和社会构成挑战。虽然有疫苗可用，但治疗策略正在不断发展，需要针对每个患者进行调整。许多临床方法侧重于重新利用针对其他疾病的已批准的治疗药物。然而，这些化合物在病毒感染方面的疗效，甚至在 SARS-CoV-2 感染背景下的有害次要影响，研究得很少。同样，针对生活方式疾病的常用治疗药物的不良反应也没有详细研究。我们使用单核细胞培养系统和更复杂的芯片模型，研究了乙酰水杨酸（ASA）盐 D,L-赖氨酸-乙酰水杨酸+甘氨酸（LASAG）对 SARS-CoV-2 体外感染的影响。ASA 通常被称为阿司匹林，是全球使用最广泛的药物之一。我们的数据表明 LASAG 对 SARS-CoV-2 复制以及 SARS-CoV-2 诱导的促炎细胞因子和凝血因子表达具有抑制作用。值得注意的是，我们的数据表明 LASAG 和抗病毒药物瑞德西韦联合使用对 SARS-CoV-2 在体外复制具有相加作用。
